Claritev Corporation

NYSE:CTEV

Medical - Healthcare Information Services

Healthcare
$22.30 +1.41%

+$0.42 today

Market cap
$380.77M
Beta
0.77
P/E (TTM)
-1.8
EPS (TTM)
-$17.16
52W Low $11.50High $74.07

Volume 0.31M

Average 0.14M

CTEV Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Claritev CorporationNYSE: CTEV

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization grows in line with its trailing trend

Q1 FY2026 depreciation & amortization of $111.65M rose 0.1% year over year, behind the +1.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.6% from the prior quarter. Over 3 fiscal years it compounded at +2.6% a year.

Context

  • Depreciation & amortization amounted to 46.5% of revenue in FY2025, down 0.4 pp from a year earlier.
  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.1% toward the trailing-twelve-month pace of +1.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$111.65M-0.6% QoQ
Last fiscal yearDec 2025
$448.45M+2.8% YoY
LTMMar 2026
$447.88M+1.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.1%——
1 year+2.8%——
3-year CAGR+2.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
448.45M USD
Year-over-year change
+2.8%
4-year CAGR
+2.1%

Depreciation & Amortization vs competitors

How CTEV compares with its peers on the latest reported figures

  • CTEV's LTM Mar 2026 depreciation & amortization of $447.88M is the highest of the 11 companies compared; the peer median is $10.63M.
  • Its year-over-year change of +1.8% is the 6th highest of 11, against a peer median of +0.2%.
  • Depreciation & amortization amounts to 45.8% of revenue for CTEV, versus a peer median of 6.3%.
CTEV Competitors Peer median
Depreciation & Amortization for CTEV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CTEVClaritev CorporationLTM Mar 2026$447.88M +1.8%+2.6%45.8%
IARTIntegra LifeSciences Holdings CorporationLTM Mar 2026$152.29M +3.3%+7.6%9.3%
EVHEvolent Health, Inc.LTM Mar 2026$118.75M +4.1%+8.7%6.3%
OPKOPKO Health, Inc.LTM Mar 2026$90.34M -5.7%-5.5%15.5%
GDRXGoodRx Holdings, Inc.LTM Mar 2026$86.1M +15.6%+16.3%10.9%
SANASana Biotechnology, Inc.LTM Mar 2026$11.49M -33.5%-6.6%—
LFMDLifeMD, Inc.LTM Mar 2026$9.76M -2.9%+88.7%4.4%
AXGNAxoGen, Inc.LTM Sep 2026$8.91M +19.5%+19.1%3.3%
IRMDIRadimed CorporationLTM Mar 2026$2.05M +160.3%+52.5%2.4%
INMDInMode Ltd.LTM Mar 2026$696K -5.6%+0.7%0.2%
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$379K -11.0%+42.8%19.9%
Peer median (excluding CTEV) $10.63M+0.2%+12.5%6.3%

Competitors are the stored peer set for CTEV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.12B1.08B961.52M930.62M965.41M
Cost of Revenue175.29M204.1M235.47M239.4M698.84M
Gross Profit942.31M875.62M726.06M691.22M266.58M
Gross Margin84.3%81.1%75.5%74.3%27.6%
Research & Development00000
Selling, General & Admin151.1M132.14M135.99M160.22M221.52M
Operating Expenses556.19M1.24B564.07M2.08B221.52M
Depreciation & Amortization412.06M415.66M425.79M436.44M448.45M
EBITDA814.99M158.32M651.93M(1.01B)475.44M
EBITDA Margin72.9%14.7%67.8%-108.3%49.2%
Operating Income386.12M(362.73M)161.98M(1.39B)45.06M
Operating Margin34.5%-33.6%16.8%-149.4%4.7%
Interest Income30K3.5M8.23M3.13M1.56M
Interest Expense267.48M303.4M333.21M326.37M400.07M
Other Income / Expenses(250.67M)(198.01M)(269.04M)(380.78M)(418.14M)
Income Before Tax135.45M(560.74M)(107.06M)(1.77B)(373.08M)
Pre-Tax Margin12.1%-51.9%-11.1%-190.3%-38.6%
Income Tax Expense33.37M12.17M(15.36M)(124.88M)(88.8M)
Net Income102.08M(572.91M)(91.7M)(1.65B)(284.28M)
Net Margin9.1%-53.1%-9.5%-176.9%-29.4%
EPS (Basic)6.40(35.87)(5.69)(101.92)(17.30)
EPS (Diluted)6.40(35.87)(5.69)(101.92)(17.30)
Weighted Avg Shares16.28M15.97M16.13M16.15M16.43M
Weighted Avg Shares (Diluted)16.29M15.97M16.13M16.15M16.43M

Claritev Corporation

NYSE:CTEV

Intrinsic Alpha fair value

Locked

Current Price

$22.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.